Back to search

Switzerland· 67648002

Tabrecta 200 mg, Filmtabletten

A capmatinib product containing capmatinibum, registered in Switzerland by Novartis Pharma Schweiz AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 4 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC L01EX17

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedTabrecta 200 mg, FilmtablettenATCL01EX17REGISTER NO.67648002PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Capmatinib is registered in 4 of 19 countries.

Countries holding a registration under ATC L01EX17 (capmatinib), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 2 of them publish a price we can compare per daily dose

Capmatinib · ATC L01EX17

4 / 19 countries

  • Canada
  • Ireland
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Swissmedic (Switzerland)
Active substance
capmatinibum
Manufacturer
Novartis Pharma Schweiz AG
Country
Switzerland (CH)
ATC code
L01EX17
ATC class
Capmatinib
Swissmedic category
A
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680676480028
    Blist 120 Stk
    CHF 5954.25

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

173 interactions on record for capmatinib.

Graded by severity as the source publishes them — 28 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Capmatinib · interactions on record

173 records

  • 28 severe
  • 136 moderate
  • 9 minor

Most severe, free to view

  • EdoxabanB01AF03severe
  • DexamethasoneH02AB02severe
  • KetoconazoleH02CA03severe
  • ClarithromycinJ01FA09severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Capmatinib in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All capmatinib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Tabrecta
  • Liechtenstein · Tabrecta
  • Norway · Tabrecta

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e6be1ffc-3aaa-4ea8-9974-c9602a6d77ca
GET /v1/drugs/e6be1ffc-3aaa-4ea8-9974-c9602a6d77ca?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "capmatinibum 200 mg",
  "valid_from": "2024-06-01",
  "limitations": "[{\"description\":\"Nach Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes. Die Kostengutsprache hat folgenden Indikationscode zu enthalten: 21282.01<br>\\nTABRECTA ist für die Behandlung von erwachsenen Patienten mit fortgeschrittenem oder metastasierendem nicht-kleinzelligem Lungenkarzinom (NSCLC) mit einer MET-Exon-14-Skipping-Mutation indiziert. Eine Anwendung bei zusätzlichen onkogenen Treibermutationen inklusive EGFR oder ALK Tumoraberrationen wird nicht vergütet. Die Vergütung erfolgt bis zur Progression der Erkrankung.<br>\\nEine Rotation innerhalb der MET-Inhibitoren wird ausschliesslich bei Kontraindikation oder  Unverträglichkeit vergütet.<br>\\nDie Novartis Pharma Schweiz AG erstattet dem Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, auf dessen erste Aufforderung hin für jede in dieser Indikation vergütete Packung TABRECTA einen festgelegten Anteil des Fabrikabgabepreises zurück. Die Novartis Pharma Schweiz AG gibt dem Krankenversicherer die Höhe der Rückerstattungen bekannt. Die Mehrwertsteuer kann nicht zusätzlich zu diesem Anteil des Fabrikabgabepreises zurückgefordert werden. Die Aufforderung zur Rückerstattung soll ab dem Zeitpunkt der Verabreichung erfolgen.<br>\\n<br>\\n\",\"costApproval\":null,\"indication\":\"21282.01\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2024-06-01\",\"validTo\":\"2027-06-30\"}]",
  "galenic_form": "Filmtabl 200 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2022-04-01",
  "self_retention_pct": 10
}

See everything about capmatinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.